Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02321527 · ClinicalTrials.gov registry record · NA
Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients
A NA study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT02321527: Completed NA study, sponsored by M.D. Anderson Cancer Center.
NCT02321527 is a NA study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02321527, a NA study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The goal of this clinical research is to learn if an ultrasound contrast agent called OPTISON (perflutren protein type A) is effective in finding sentinel lymph nodes before surgery. Contrast agents can help make ultrasound images more accurate. The sentinel lymph node is the first node that may be the target of cancer cells that spread from the tumor.
Interventions
- BEHAVIORAL Phone Call
- DRUG Perflutren Protein-Type A Microspheres Injectable Suspension
- DEVICE Contrast-Enhanced Ultrasound (CEUS)
- PROCEDURE Biopsy + Radioactive Seed Placement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02321527
The ClinicalTrials.gov registry entry for NCT02321527 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Phone Call is the first listed.
NCT02321527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02321527 about?
NCT02321527 is a clinical study titled "Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients". The goal of this clinical research is to learn if an ultrasound contrast agent called OPTISON (perflutren protein type A) is effective in finding sentinel lymph nodes before surgery. Contrast agents can help make ultrasound images more accurate. The sentinel lymph node is the first node that may be ...
What is the current status of trial NCT02321527?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2015-07. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02321527?
The interventions under investigation include: Phone Call (BEHAVIORAL), Perflutren Protein-Type A Microspheres Injectable Suspension (DRUG), Contrast-Enhanced Ultrasound (CEUS) (DEVICE), Biopsy + Radioactive Seed Placement (PROCEDURE).
Who is sponsoring clinical trial NCT02321527?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.